Market Research Logo

Global Central Nervous System Therapeutic Market : Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North Ame

Global Central Nervous System Therapeutic Market : Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, China, Japan, India, Brazil)

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Central nervous System Therapeutic Market. The report analyzes the Central Nervous System Therapeutic Market By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection). The Central Nervous System Therapeutic Market has been analyzed By Region (North America, Europe, Asia Pacific and Rest of the World) and By Country (US, Canada, UK, Germany, China, Japan, India, and Brazil) for the historical period of 2014-2018 and the forecast period of 2019-2024.

According to Azoth Analytics research report “Global Central Nervous System Therapeutic Market : Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, China, Japan, India, Brazil)”, global market is projected to display a robust growth represented by a CAGR of 6.80% during 2019 – 2024.

The mental health has been witnessing growth at a noteworthy rate over the past few years backed by rise in stress and depression among people as well as increasing awareness and acceptance amongst people about mental health. Amongst the regions, Asia Pacific accounts for the largest regional share in the global central nervous system therapeutic market in 2018. Key factors driving the robust growth rate of Asia Pacific region include rising geriatric population along with increasing incidences of neurodegenerative diseases, increase in chronic ailments and growing per capita healthcare expenditure worldwide.

The report titled “Global Central Nervous System Therapeutic Market: Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, China, Japan, India, Brazil)” has covered and analyzed the potential of Global Central Nervous System Therapeutic market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global central nervous system therapeutic market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Central Nervous System Therapeutic Market (Actual Period: 2014-2018, Forecast Period: 2019-2024

  • Global Central Nervous System Therapeutic Market – Size, Growth, Forecast
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)
Regional Markets – North America, Europe, APAC and Rest of the World (Actual Period: 2014-2018, Forecast Period: 2019-2024)
  • Central Nervous System Therapeutic Market – Size and Growth
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)
Country Analysis – US, Canada, UK, Germany, China, Japan, India, Brazil (Actual Period: 2014-2018, Forecast Period: 2019-2024)
  • Central Nervous System Therapeutic Market – Size and Growth
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)
Other Report Highlights
  • Market Dynamics – Drivers and Restraints
  • Market Trends
  • Porter Five Force Analysis
  • Policy and Regulatory Landscape
  • Competitive Landscape
  • Company Analysis – Biogen, Pfizer, Teva Pharmaceuticals, Novartis, Johnson & Johnson, Shire, Merc & Co, AstraZeneca, Otsuka Pharmaceutical, Eli Lilly.


1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
3.1 Lucrative scope in neurodegenerative therapeutic market
3.2 APAC region to witness augmented growth in the forecast period
4. Central Nervous System Therapeutic Market: Product Outlook
Table 1: Flowchart of Nervous System
Table 2: Tumor Grade Descriptions
Table 3: Overview of major subcategories of central nervous system disorders
5. Global Central Nervous System Therapeutic Market : Growth and Forecast
5.1 By Value (2014-2018)
Table 4: Global Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
5.2 By Value (2019-2024)
Table 5: Global Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
Table 6: Global Overweight Population (Age above 18), 2015-2018 (% of total)
Table 7: Global Overweight Population (Age above 18), By Sex, 2018 (% of total)
Table 8: Smoking Prevalence Among Adults, By Gender, 2015
Table 9: Cigarette Sales Share, By Region, 2017 (% of total)
Table 10: Distributions of persons aged 60 years or above by region in millions, 2015 and 2030F
Table 11: Global Aged Population (Above 65), 2014-2018 (% of total)
Table 12: Regions with dedicated policies for neurological disorders, In 2017, ( In %)
Table 13: Countries with dedicated policies for neurological disorders, Based on income group, In 2017, In %
Table 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2014-2018 (In %)
Table 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Table 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
Table 17: Most frequent neurological diseases reported in primary care, In 2017
Table A: Top 10 diseases causing the most deaths worldwide, In 2017
Table 18: Most frequent neurological diseases reported in primary care, In 2017
Table 19: Regional Expected Healthcare Industry Growth Rate By Year 2020
Table 20: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
Table 21: Projected global population aged 60 years & above (In Billions)
6. Global Central Nervous System Therapeutic Market : Segmental Analysis
6.1 Global Central Nervous System Therapeutic Market Size, By Type: Breakdown (%)
6.1.1 Global Central Nervous System Therapeutic Market Size, By Type, 2018 (%)
Table 22: Global Central Nervous System Therapeutic Market Size, By Type, 2017 (In %)
6.1.2 Global Central Nervous System Therapeutic Market Size, By Type, 2024 (%)
Table 23: Global Central Nervous System Therapeutic Market Size, By Type, 2023 (In %)
6.2 Global Cancer Market, By Value (2014-2024)
Table 24: Global Cancer Market, By Value, 2014-2018 (USD Billion)
6.3 Global Neurovascular Market, By Value (2014-2024)
Table 26: Global Neurovascular Market, By Value, 2014-2018 (USD Billion)
Table 27: Global Neurovascular Market, By Value, Forecast, 2019-2024(USD Billion)
6.4 Global Neurodegenerative disorder Market, By Value (2014-2024)
Table 28: Global Neurodegenerative Market, By Value, 2014-2018 (USD Billion)
Table 29: Global Neurodegenerative Market, By Value, Forecast, 2019-2024(USD Billion)
Table 30: Global Neurodegenerative Therapeutic Market Size, By Value, 2018 (%)
Table 31: Global Neurodegenerative Therapeutic Market Size, By Value, 2024 (%)
6.5 Global Mental Health Market, By Value (2014-2024)
Table 32: Global Mental Health Market, By Value, 2014-2018 (USD Billion)
Table 33: Global Mental Health Market, By Value, Forecast, 2019-2024(USD Billion)
6.6 Global Trauma Market, By Value(2014-2024)
Table 32: Global Mental Health Market, By Value, 2014-2018 (USD Billion)
Table 33: Global Mental Health Market, By Value, Forecast, 2019-2024(USD Billion)
Table 36: Global TraumaTherapeutic Market Size, By Value, 2018 (%)
Table 37: Global TraumaTherapeutic Market Size, By Value, 2024 (%)
6.7 Global Infection Market, By Value (2014-2024)
Table 38: Global Brain Infection Market, By Value, 2014-2018 (USD Billion)
Table 39: Global Brain Infection Market, By Value, Forecast, 2019-2024(USD Billion)
Table 40: Global Healthcare Landscape, By Select Region
7. Global Central Nervous System Therapeutic Market : Regional Analysis
7.1 Global Central Nervous System Therapeutic Market Size, By Region : Breakdown (%)
7.1.1 Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)
Table 41: Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)
7.1.2 Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)
Table 42: Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)
7.2 North America Central Nervous System Therapeutic Market: Growth and Forecast
7.2.1 By Value (2014-2018)
Table 43: North America Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
7.2.2 By Value (2019-2024)
Table 44: North America Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
Table 45: North America Population Ages 65 and above, 2012-2017 (% of Total)
Table 46: North America Healthcare Cost Per Capita, 2017 (USD)
Table 47: Most frequent neurological diseases reported in primary care, In North America, 2017
Table 48: North America GDP, 2012-2017 (USD Trillion)
Table 49: North America GDP per capita, current prices, 2013-2023F (In USD)
7.2.3 By Type, By Value (2014-2018)
Table 50: North America Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
7.2.4 By Type, By Value (2019-2024)
Table 51: North America Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
7.3 North America Central Nervous System Therapeutic Market: Country Analysis (U.S and Canada)
7.3.1 U.S Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 52: U.S. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 53: U.S. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 54: Most costly neurological disorders in United States, In 2017
Table 55: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Table 56: Proportion of people with Alzheimer disease, In United States, In 2017
Table 57: Projected number of people with Alzheimer disease aged 65 and older, In United States, In million, In 2017
Table 58: Aggregate cost of care for Alzheimer, By payer, In United States, In 2017
Table 59: U.S., Population ages 65 and above, Forecast (In Millions)
Table 60: U.S., GDP (Current USD), 2014-2018 (In USD Trillion)
7.3.2 Canada Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 61: Canada Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 62: Canada Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 63: Canada, Population ages 65 and above, 2012-2017 (% of total)
Table 64: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
Table 65: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Table 66: Incidence, mortality and survival statistics for brain cancer in Canada, In 2017
Table 67: Prevalence of brain cancer in Canada
7.4 Europe Central Nervous System Therapeutic Market: Growth and Forecast
7.4.1 By Value (2014-2018)
Table 68: Europe Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
7.4.2 By Value (2019-2024)
Table 69: Europe Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
Table B: Smoking prevalence worldwide, In 2017, By Sex, In %
Table 70: Most frequent neurological diseases reported in primary care, In Europe, 2017
Table 71: Distribution of Schizophrenia patients worldwide, In 2017, In thousands
Table 72: Per Capita Health Expenditure, By Select Country, 2017 (USD)
Table 73: European Union, Population ages 65 and above, 2013-2017 (% of total)
Table 74: European Country Population Aged 65 and Above, 2012-2017 (% of Total)
Table 75: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
7.4.3 By Type, By Value (2014-2018)
Table 76: Europe Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
7.4.4 By Type, By Value (2019-2024)
Table 77: Europe Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
7.5 Europe Central Nervous System Therapeutic Market: Country Analysis (U.K and Germany)
7.5.1 U.K Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 78: U.K. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 79: U.K. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 80: Most costly neurological disorders in United Kingdom, In 2017
Table C: Facts about mental health in United Kingdom
Table 81: Proportion of people with symptoms of mental disorders in United Kingdom
Table 82: Proportion of symptoms of mental disorder, By sex, In 2017, In United Kingdom
Table 83: U.K, Health Expenditure, (% of GDP), 2012-2017 (USD)
Table 84: U.K, Population Ages 65 and Above (% of total), 2012-2017
Table 85: UK, Healthcare Infrastructure Related Statistics
Table 86: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
7.5.2 Germany Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 87: Germany Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 88: Germany Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 89: Germany, Population ages 65 and above, 2012-2017 (% total)
Table 90: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Table 91: Germany, Healthcare Related Statistics, 2017
7.6 APAC Central Nervous System Therapeutic Market: Growth and Forecast
7.6.1 By Value (2014-2018)
Table 92: APAC Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
7.6.2 By Value (2019-2024)
Table 93: APAC Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
Table 94: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
Table 95: Population ages 65 and above, By Select Country, 2017 (% of total)
Table 96: Men Smoking Prevalence in Asia, 2016, (% of Total Population)
Table 97: Most frequent neurological diseases reported in primary care, In Asia Pacific, 2017
Table D: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
Table E: Rate of suicides worldwide, In 2017, In number
7.6.3 By Type, By Value (2014-2018)
Table 98: APAC Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
7.6.4 By Type, By Value (2019-2024)
Table 99: APAC Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
7.7 APAC Central Nervous System Therapeutic Market: Country Analysis (Japan, India and China)
7.7.1 China Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 100: China Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 101: China Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 102: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016
Table 103: China, Tobacco Attributable Deaths, 2030
Table 104: China, Total Population, 2013-2021F (In Billion)
Table 105: China, GDP Growth Per Year, 2015-2019 (In %)
Table 106: China, Share of Urban Population, 2012-2017 (In %)
Table 107: China Healthcare Expenditure Outlook (2017) (%)
Table 108: China, Population Above 65 (% of Total), 2013-2017
7.7.2 Japan Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 109: Japan Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 110: Japan Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 111: Japan, Population ages 65 and above, 2012-2017 (% of total)
Table 112: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence)
Table 113: Japan Healthcare Expenditure Outlook (%)
7.7.3 India Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 114: India Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 115: India Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 116: India, Population ages 65 and above, 2013-2017
Table 117: India, Total Population, 2013-2023F (In Billion)
Table 118: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)
Table 119: India, Share of Urban Population, 2012-2017 (In %)
Table 120: India, GDP Growth Per Year, 2015-2019 (In %)
Table F: National List of Essential medicines in India, By Select Disease, In 2017
7.8 ROW Central Nervous System Therapeutic Market: Growth and Forecast
7.8.1 By Value (2014-2018)
Table 121: ROW Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
7.8.2 By Value (2019-2024)
Table 122: ROW Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
Table 123: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
Table 124: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
Table 125: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
Table 126: Middle East and North Africa, Population ages 65 and above (% of total)
Table 127: Most frequent neurological diseases reported in primary care, In Africa, In 2017
Table 128: Methods of financing neurological care
7.8.3 By Type, By Value (2014-2018)
Table 129: ROW Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
7.8.4 By Type, By Value (2019-2024)
Table 130: ROW Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
7.9 ROW Central Nervous System Therapeutic Market: Country Analysis (Brazil)
7.9.1 Brazil Central Nervous System Therapeutic Market, By Value (2014-2024)
Table 131: Brazil Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
Table 132: Brazil Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
Table 133: Brazil, Population ages 65 and above, 2012-17 (% of total)
Table 134: Brazil, GDP, 2012-2017 (In USD Trillion)
Table G: Healthcare spending pattern in Brazil (In USD)
Table 135: Brazil health expenditure as a share of GDP, 2016
8. Global Central Nervous System Therapeutic Market Dynamics
8.1 Global Central Nervous System Therapeutic Market Drivers
8.2 Global Central Nervous System Therapeutic Market Restraints
9. Global Central Nervous System Therapeutic Market Trends
10. Porter Five Force Analysis
11. SWOT Analysis
12. Supply Chain Analysis
13. Policy and Regulatory Landscape
14. Company Profiles
14.1 Biogen
Table 136: Biogen, Sales Revenue, 2013-2017 (USD Billion)
Table 137: Biogen, Sales, By Business Segment, FY ended March 2017 (%)
Table 138: Biogen, Sales, By Geographic region, FY ended March 2017 (%)
14.2 Pfizer
Table 136: Biogen, Sales Revenue, 2013-2017 (USD Billion)
Table 137: Biogen, Sales, By Business Segment, FY ended March 2017 (%)
Table 138: Biogen, Sales, By Geographic region, FY ended March 2017 (%)
14.3 Teva Pharmaceuticals
Table 142: Teva Pharmaceuticals, Net Sales, 2014-2018 (In Million USD)
Table 143: Teva Pharmaceuticals, Net Sales, By Business Sector, 2018 (In %)
Table 144: Teva Pharmaceuticals, Net Sales, By Geographic Region, 2018 (In %)
14.4 Novartis
Table 145: Novartis, Sales Revenue, 2013-2017 (USD Million)
Table 146: Novartis, Sales, By Business Segment, FY ended March 2018 (%)
Table 147: Novartis, By Region, FY ended March 2018 (%)
14.5 Johnson & Johnson
Table 148: Johnson & Johnson, Sales Revenue, 2013-2017 (USD Million)
Table 149: Johnson & Johnson , Sales, By Business Segment, FY ended March 2018 (%)
Table 150: Johnson & Johnson, By Region, FY ended March 2018 (%)
14.6 Shire
Table 151: Shire, Sales Revenue, 2015-2017 (USD Million)
Table 152: Shire, Sales, By Business Segment, FY ended March 2017 (%)
Table 153: Shire, By Region, FY ended March 2017 (%)
14.7 Merck & Co.
Table 154: Merck & Co., Sales Revenue, 2013-2017 (USD Million)
Table 155: Merck & Co. , Sales, By Business Segment, FY ended March 2017 (%)
Table 156: Merck & Co., By Region, FY ended March 2017 (%)
14.8 AstraZeneca
Table 157: AstraZeneca, Sales Revenue, 2013-2017 (USD Million)
Table 158: AstraZeneca, Sales, By Business Segment, FY ended March 2017 (%)
Table 159: AstraZeneca, By Region, FY ended March 2017 (%)
14.9 Otsuka Pharmaceutical
Table 160: Otsuka Pharmaceutical, Sales, By Business Segment, FY ended March 2017 (%)
Table 161: Otsuka Pharmaceutical, By Region, FY ended March 2017 (%)
14.10 Eli Lilly
Table 162: Eli Lilly, Sales Revenue, 2013-2017 (USD Million)
Table 163: Eli Lilly, Sales, By Business Segment, FY ended March 2017 (%)
Table 164: Eli Lilly, By Region, FY ended March 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report